The Evolution at a Glance
The incretin field has progressed from single-pathway approaches to dual and triple designs. GLP-1S, GLP-2T, and GLP-3R form a logical sequence for building and comparing metabolic hypotheses.
Side-by-Side Comparison
| Compound | Pathways Activated | Core Research Focus | Research Value |
|---|---|---|---|
| GLP-1S | GLP-1 | Satiety, gastric kinetics, glucose-dependent insulin activity | Foundational baseline |
| GLP-2T | GLP-1 + GIP | Dual incretin synergy for appetite & glucose | Next-step innovation |
| GLP-3R | GLP-1 + GIP + Glucagon | Satiety + glucose + energy expenditure | Triple-pathway frontier |
Choosing the Right Tool
Investigators often begin with GLP-1S to establish a baseline, step up to GLP-2T to evaluate dual-incretin synergy, and then move to GLP-3R to incorporate energy expenditure via glucagon. Selection depends on the research question, endpoints, and desired pathway breadth.
Study Design Notes
- Use standardized feeding paradigms and appetite rating measures.
- Include calorimetry when expenditure is a primary endpoint.
- Consider crossover or multi-arm designs to compare S vs. T vs. R within a single protocol.
- Maintain rigorous documentation for reproducibility (batch data, environmental controls, analytical methods).
Synthesis Peptides Perspective
We provide S, T, and R as a complete toolkit for incretin-focused research, with precision formulation and Research Use Only labeling to support robust methodological standards.
COMPLIANCE NOTICE: For laboratory research use only. Not for human consumption, diagnostic, or therapeutic use. The information provided summarizes published research and is not medical advice. No statements herein have been evaluated by the FDA. Products are not intended to diagnose, treat, cure, or prevent any disease.
This article is for informational and research purposes only. All products discussed are sold strictly for laboratory and research use, not for human or veterinary use, consumption, or diagnostic application.
